Menu Search
Equities

STAAR Surgical Co

STAA:NMQ

STAAR Surgical Co

Actions
Health CareMedical Equipment and Services
  • Price (USD)31.60
  • Today's Change0.21 / 0.67%
  • Shares traded91.00
  • 1 Year change-22.30%
  • Beta0.5926
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy5
Outperform3
Hold4
Sell1
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for STAAR Surgical Co have a median target of 52.82, with a high estimate of 60.00 and a low estimate of 37.00. The median estimate represents a 67.15% increase from the last price of 31.60.
High89.9%60.00
Med67.2%52.82
Low17.1%37.00

Earnings history & estimates in USD

On Aug 07, 2024, STAAR Surgical Co reported 2nd quarter 2024 earnings of 0.39 per share. This result exceeded the 0.24 consensus of the 9 analysts covering the company and under-performed last year's 2nd quarter results by 2.50%.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate+39.37%
STAAR Surgical Co reported annual 2023 earnings of 1.01 per share on Feb 26, 2024.
Average growth rate+85.63%
More ▼

Revenue history & estimates in USD

STAAR Surgical Company had 2nd quarter 2024 revenues of 99.01m. This bettered the 95.20m consensus of the 11 analysts covering the company. This was 34.65% above the prior year's 2nd quarter results.
Average growth rate+2.85%
STAAR Surgical Company had revenues for the full year 2023 of 322.42m. This was 13.37% above the prior year's results.
Average growth rate+21.65%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.